The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $56.12

Today's change+0.37 +0.66%
Updated December 18 9:47 AM EST. Delayed by at least 15 minutes.
 

Teva Pharmaceutical Industries Ltd

NYSE: TEVA
Last

(U.S.) $56.12

Today's change+0.37 +0.66%
Updated December 18 9:47 AM EST. Delayed by at least 15 minutes.

Teva Pharmaceutical Industries Ltd up (U.S.)$0.37

Teva Pharmaceutical Industries Ltd is up today by (U.S.)$0.37 or 0.66% to (U.S.)$56.12. Shares have lost 1.27% over the last five days, but sit 4.67% below their 52-week high. This security has outperformed the S&P 500 by 28.25% during the last year.

Key company metrics

  • Open(U.S.) $56.02
  • Previous close(U.S.) $55.75
  • High(U.S.) $56.25
  • Low(U.S.) $55.92
  • Bid / Ask(U.S.) $56.13 / (U.S.) $56.15
  • YTD % change+40.02%
  • Volume330,359
  • Average volume (10-day)4,406,669
  • Average volume (1-month)3,584,821
  • Average volume (3-month)4,199,443
  • 52-week range(U.S.) $38.97 to (U.S.) $58.87
  • Beta0.64
  • Trailing P/E17.46×
  • P/E 1 year forward11.01×
  • Forward PEG8.09×
  • Indicated annual dividend(U.S.) $1.35
  • Dividend yield2.41%
  • Trailing EPS(U.S.) $3.21
Updated December 18 9:47 AM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+13.38%

Based on its net profit margin of 13.38%, Teva Pharmaceutical Industries Ltd is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX1.00%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue5,0585,0455,0015,430
Total other revenue--------
Total revenue5,0585,0455,0015,430
Gross profit2,8092,6612,6972,894
Total cost of revenue2,2492,3842,3042,536
Total operating expense3,9464,1204,0294,870
Selling / general / administrative1,2401,2111,2691,448
Research & development412344353411
Depreciation / amortization3717--
Interest expense (income), net operating--------
Unusual expense (income)4216986475
Other operating expenses, total--------
Operating income1,112925972560
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax1,028847891501
Income after tax868745748387
Income tax, total160102143114
Net income876748744380
Total adjustments to net income0------
Net income before extra. items876748744380
Minority interest13343
Equity in affiliates-5---8-10
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items876748744380
Inc. avail. to common incl. extra. items876748744380
Diluted net income878748744380
Dilution adjustment200--
Diluted weighted average shares861857852847
Diluted EPS excluding extraordinary itemsvalue per share1.020.870.870.45
Dividends per sharevalue per share0.340.350.340.32
Diluted normalized EPSvalue per share1.061.050.960.88